SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                                    FORM 8-K

                                 CURRENT REPORT
                         Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934


         Date of Report (Date of earliest event reported): April 1, 2005

                         Saliva Diagnostic Systems, Inc.
--------------------------------------------------------------------------------
             (Exact name of Registrant as specified in its charter)


                                    Delaware
                 ----------------------------------------------
                 (State or other jurisdiction of incorporation)


           000-21284                                     91-1549305
       ------------------                         -------------------------
          (Commission                                  (IRS Employer
          File Number)                               Identification No.)

           2294 Nostrand Ave. Brooklyn, NY                    11210
---------------------------------------------------      ----------------
      (Address of principal executive offices)              (Zip Code)

                                 (718) 552-3599

--------------------------------------------------------------------------------
              (Registrant's telephone number, including area code)


                                 NOT APPLICABLE

--------------------------------------------------------------------------------
          (Former name or former address, if changed since last report)

<PAGE>

Item 5.02 Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers.


      Saliva Diagnostic Systems, Inc., (SDS) has appointed Steven M. Peltzman as
Chairman of the Board of Directors and Chief Executive Officer, effective March
25, 2005.


      Mr. Peltzman has more than thirty years of business experience in
technology-based, health-care companies. In 1984, he helped start and served as
President and CEO of Applied bioTechnology, Inc. whose cancer business was sold
to OSI Pharmaceuticals, Inc. in 1991, when he became Chief Operating Officer of
the consolidated entity; from 1994 through 1997 he served as President and COO
of OSIP and remained on its Board of Directors through 1999. From 1980 to 1984,
Mr. Peltzman held senior executive positions with Millipore and for ten years
preceding that was with Corning Glass Works' Medical diagnostic and device
businesses. During the past several years he has been active in several small
health care and technology start-ups as their interim CEO or COO or in an
advisory capacity to their Boards of Directors.


      During the Employment Period, the Company will pay a base salary at the
annual rate of one hundred twenty thousand dollars ($120,000). Said base salary
shall increase to the annual rate of One Hundred Eighty Thousand ($180,000.00)
upon the closing of a financing for the Company with gross proceeds of at least
three million dollars ($3,000,000). The Board of Directors may determine, from
time to time, in its sole discretion, to pay the Employee bonuses or additional
compensation. Mr. Peltzman shall be entitled to participate in all fringe
benefits the Company provides for its employees generally, and such other
benefits as the Company provides generally for its senior executives. Until such
benefit programs are adopted, the Company shall reimburse Mr. Peltzman for 75%
of Health Insurance and for up to $2,000/yr of Life Insurance premiums. In
addition the Company granted 550,000 options to Mr. Peltzman to purchase the
common stock of the Company (the "Common Stock"), as follows:


(1) Stock options, exercisable from June 1, 2005 until June 1, 2015, entitling
Mr. Peltzman to purchase 100,000 shares of the Company's common stock ("Common
Stock") at an exercise price of $ 0.10-per share.

(2) Stock options (the "Options") to acquire 450,000 shares of Common Stock. If
Mr. Peltzman remains employed as of a vesting date, the Options shall vest in
three equal amounts annually, commencing on October 1, 2005 at which time
one-third, (150,000) of the Options shall vest, and on each of the two
anniversaries thereafter, an additional one-third of the Options shall vest,
provided that, Mr. Peltzman is terminated without Cause within six months of a
vesting date, all Options due to vest as of such date shall vest as of the date
of termination. All vested Options shall terminate ten years from issuance. The
exercise price shall be equal to the lessor of (i) 66-2/3% of the price per
share of Common Stock as established in any Company offering and sale of Common
Stock occurring prior to April 30, 2006, and (ii) $1.00 per share. In the event
of a termination of Mr. Peltzman's employment for any reason other than for
Cause, Mr. Peltzman shall have until their expiration to exercise any vested
portion of an Option. In the event of an acquisition or change in control of the
Company, all unvested options shall immediately vest.

<PAGE>

                                    SIGNATURE


      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                      Saliva Diagnostic Systems, Inc.

Date: April 01, 2005                  By:  /s/ Leo Ehrlich
                                           ------------------------
                                           Leo Ehrlich
                                           President & Secretary
<PAGE>

Saliva Diagnostic Systems Announces New CEO

Steve Peltzman to Lead Next Phase of Company's Growth

New York City, N.Y.-- April 4, 2005 -- Saliva Diagnostics Systems, Inc. (OTCBB:
SVAD - News) is pleased to announce the appointment of Mr. Steve Peltzman as
CEO, effective March 25, 2005. Mr. Peltzman has been working closely with the
Company as a consultant for the last 6 months. Mr. Peltzman has more than thirty
years of business experience in technology-based, health-care companies. In
1984, he helped start and served as President and CEO of Applied bioTechnology,
Inc. whose cancer business was sold to OSI Pharmaceuticals in 1991, when he
became Chief Operating Officer of the consolidated entity; from 1994 through
1997 he served as President and COO of OSIP and remained on its Board of
Directors through 1999. From 1980 to 1984, Mr. Peltzman held senior executive
positions with Millipore and for ten years preceding that was with Corning Glass
Works' Medical diagnostic and device businesses. During the past several years
he has been active in several small health care and technology start-ups as
their interim CEO or COO or in an advisory capacity to their Boards of
Directors.

Mr. Peltzman stated his reasons for joining the firm: "SDS is poised to become a
key player in the embryonic, point-of-care, rapid testing market, targeting
sexually transmitted and other important infectious diseases. The need to
accurately, inexpensively, safely and quickly identify millions of infected
individuals throughout the globe is a critical first step in cost effectively
dealing with the devastating consequences of HIV, hepatitis and a myriad of
other pathogens. SDS's proprietary format for rapid testing appears to be an
ideal fit to commercially solve certain of these problems that seriously impact
our public health systems and world economies."

About Saliva Diagnostic Systems (SDS)

Saliva Diagnostic Systems manufactures and markets a patented rapid point of
care testing device for infectious diseases, as well as oral fluid specimen
collection devices using a patented volume adequacy indicator for drugs of abuse
testing and other clinical uses. These products are sold in the United States as
well as internationally to various distributors for use in clinical
laboratories, hospitals, clinics, community-based organizations and other public
health organizations. Please visit our website at www.salv.com

FORWARD-LOOKING STATEMENTS

Statements contained herein that are not historical facts are forward-looking
statements within the meaning of the Securities Act of 1933, as amended. Those
statements include statements regarding the intent, belief or current
expectations of the Company and its management. Such statements reflect
management's current views, are based on certain assumptions and involve risks

<PAGE>

and uncertainties. Actual results, events, or performance may differ materially
from the above forward-looking statements due to a number of important factors,
and will be dependent upon a variety of factors, including, but not limited to,
the Company's ability to obtain additional financing and the demand for the
Company's products. The Company undertakes no obligation to publicly update
these forward-looking statements to reflect events or circumstances that occur
after the date hereof or to reflect any change in the Company's expectations
with regard to these forward-looking statements or the occurrence of
unanticipated events. Factors that may impact the Company's success are more
fully disclosed in the Company's most recent public filings with the U.S.
Securities and Exchange Commission ("SEC").

Contact:
INVESTOR RELATIONS, 508-655-0991
{"company-data": {"conformed-name": "SALIVA DIAGNOSTIC SYSTEMS INC", "cik": "0000885534", "assigned-sic": "3841", "irs-number": "911549305", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-21284", "film-number": "05751106"}, "business-address": {"street1": "2294 NOSTRAND AVE.", "city": "BROOKLYN", "state": "NY", "zip": "11210", "phone": "7185523599"}, "mail-address": {"street1": "2294 NOSTRAND AVE.", "city": "BROOKLYN", "state": "NY", "zip": "11210"}}
SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                                    FORM 8-K

                                 CURRENT REPORT
                         Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934

         Date of Report (Date of earliest event reported): April 1, 2005

                         Saliva Diagnostic Systems, Inc.
--------------------------------------------------------------------------------
             (Exact name of Registrant as specified in its charter)

                                    Delaware
                 ----------------------------------------------
                 (State or other jurisdiction of incorporation)

           000-21284                                     91-1549305
       ------------------                         -------------------------
          (Commission                                  (IRS Employer
          File Number)                               Identification No.)

           2294 Nostrand Ave. Brooklyn, NY                    11210
---------------------------------------------------      ----------------
      (Address of principal executive offices)              (Zip Code)

                                 (718) 552-3599

--------------------------------------------------------------------------------
              (Registrant's telephone number, including area code)

                                 NOT APPLICABLE

--------------------------------------------------------------------------------
          (Former name or former address, if changed since last report)
Item 5.02 Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers.

      Saliva Diagnostic Systems, Inc., (SDS) has appointed Steven M. Peltzman as
Chairman of the Board of Directors and Chief Executive Officer, effective March
25, 2005.

      Mr. Peltzman has more than thirty years of business experience in
technology-based, health-care companies. In 1984, he helped start and served as
President and CEO of Applied bioTechnology, Inc. whose cancer business was sold
to OSI Pharmaceuticals, Inc. in 1991, when he became Chief Operating Officer of
the consolidated entity; from 1994 through 1997 he served as President and COO
of OSIP and remained on its Board of Directors through 1999. From 1980 to 1984,
Mr. Peltzman held senior executive positions with Millipore and for ten years
preceding that was with Corning Glass Works' Medical diagnostic and device
businesses. During the past several years he has been active in several small
health care and technology start-ups as their interim CEO or COO or in an
advisory capacity to their Boards of Directors.

      During the Employment Period, the Company will pay a base salary at the
annual rate of one hundred twenty thousand dollars ($120,000). Said base salary
shall increase to the annual rate of One Hundred Eighty Thousand ($180,000.00)
upon the closing of a financing for the Company with gross proceeds of at least
three million dollars ($3,000,000). The Board of Directors may determine, from
time to time, in its sole discretion, to pay the Employee bonuses or additional
compensation. Mr. Peltzman shall be entitled to participate in all fringe
benefits the Company provides for its employees generally, and such other
benefits as the Company provides generally for its senior executives. Until such
benefit programs are adopted, the Company shall reimburse Mr. Peltzman for 75%
of Health Insurance and for up to $2,000/yr of Life Insurance premiums. In
addition the Company granted 550,000 options to Mr. Peltzman to purchase the
common stock of the Company (the "Common Stock"), as follows:

(1) Stock options, exercisable from June 1, 2005 until June 1, 2015, entitling
Mr. Peltzman to purchase 100,000 shares of the Company's common stock ("Common
Stock") at an exercise price of $ 0.10-per share.

(2) Stock options (the "Options") to acquire 450,000 shares of Common Stock. If
Mr. Peltzman remains employed as of a vesting date, the Options shall vest in
three equal amounts annually, commencing on October 1, 2005 at which time
one-third, (150,000) of the Options shall vest, and on each of the two
anniversaries thereafter, an additional one-third of the Options shall vest,
provided that, Mr. Peltzman is terminated without Cause within six months of a
vesting date, all Options due to vest as of such date shall vest as of the date
of termination. All vested Options shall terminate ten years from issuance. The
exercise price shall be equal to the lessor of (i) 66-2/3% of the price per
share of Common Stock as established in any Company offering and sale of Common
Stock occurring prior to April 30, 2006, and (ii) $1.00 per share. In the event
of a termination of Mr. Peltzman's employment for any reason other than for
Cause, Mr. Peltzman shall have until their expiration to exercise any vested
portion of an Option. In the event of an acquisition or change in control of the
Company, all unvested options shall immediately vest.
SIGNATURE

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                      Saliva Diagnostic Systems, Inc.

Date: April 01, 2005                  By:  /s/ Leo Ehrlich
                                           ------------------------
                                           Leo Ehrlich
                                           President & Secretary
Saliva Diagnostic Systems Announces New CEO

Steve Peltzman to Lead Next Phase of Company's Growth

New York City, N.Y.-- April 4, 2005 -- Saliva Diagnostics Systems, Inc. (OTCBB:
SVAD - News) is pleased to announce the appointment of Mr. Steve Peltzman as
CEO, effective March 25, 2005. Mr. Peltzman has been working closely with the
Company as a consultant for the last 6 months. Mr. Peltzman has more than thirty
years of business experience in technology-based, health-care companies. In
1984, he helped start and served as President and CEO of Applied bioTechnology,
Inc. whose cancer business was sold to OSI Pharmaceuticals in 1991, when he
became Chief Operating Officer of the consolidated entity; from 1994 through
1997 he served as President and COO of OSIP and remained on its Board of
Directors through 1999. From 1980 to 1984, Mr. Peltzman held senior executive
positions with Millipore and for ten years preceding that was with Corning Glass
Works' Medical diagnostic and device businesses. During the past several years
he has been active in several small health care and technology start-ups as
their interim CEO or COO or in an advisory capacity to their Boards of
Directors.

Mr. Peltzman stated his reasons for joining the firm: "SDS is poised to become a
key player in the embryonic, point-of-care, rapid testing market, targeting
sexually transmitted and other important infectious diseases. The need to
accurately, inexpensively, safely and quickly identify millions of infected
individuals throughout the globe is a critical first step in cost effectively
dealing with the devastating consequences of HIV, hepatitis and a myriad of
other pathogens. SDS's proprietary format for rapid testing appears to be an
ideal fit to commercially solve certain of these problems that seriously impact
our public health systems and world economies."

About Saliva Diagnostic Systems (SDS)

Saliva Diagnostic Systems manufactures and markets a patented rapid point of
care testing device for infectious diseases, as well as oral fluid specimen
collection devices using a patented volume adequacy indicator for drugs of abuse
testing and other clinical uses. These products are sold in the United States as
well as internationally to various distributors for use in clinical
laboratories, hospitals, clinics, community-based organizations and other public
health organizations. Please visit our website at www.salv.com

FORWARD-LOOKING STATEMENTS

Statements contained herein that are not historical facts are forward-looking
statements within the meaning of the Securities Act of 1933, as amended. Those
statements include statements regarding the intent, belief or current
expectations of the Company and its management. Such statements reflect
management's current views, are based on certain assumptions and involve risks
and uncertainties. Actual results, events, or performance may differ materially
from the above forward-looking statements due to a number of important factors,
and will be dependent upon a variety of factors, including, but not limited to,
the Company's ability to obtain additional financing and the demand for the
Company's products. The Company undertakes no obligation to publicly update
these forward-looking statements to reflect events or circumstances that occur
after the date hereof or to reflect any change in the Company's expectations
with regard to these forward-looking statements or the occurrence of
unanticipated events. Factors that may impact the Company's success are more
fully disclosed in the Company's most recent public filings with the U.S.
Securities and Exchange Commission ("SEC").

Contact:
INVESTOR RELATIONS, 508-655-0991